Valuation: Orthocell Limited

Market Cap 193M 135M 119M 110M 101M 190M 13.02B 1.31B 512M 6.4B 507M 497M 22.13B P/E 2026 *
-17.8x
P/E 2027 * -35.5x
Enterprise Value 153M 107M 93.73M 87.16M 79.98M 150M 10.28B 1.04B 404M 5.05B 401M 392M 17.47B EV / Sales 2026 *
13.3x
EV / Sales 2027 * 7.6x
Free-Float
83.71%
Yield 2026 *
-
Yield 2027 * -
1 day-0.70%
1 week-2.07%
Current month-2.07%
1 month-1.39%
3 months-18.39%
6 months-26.80%
Current year-34.56%
1 week 0.71
Extreme 0.71
0.78
1 month 0.7
Extreme 0.7
0.91
Current year 0.7
Extreme 0.7
1.16
1 year 0.7
Extreme 0.7
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member - 01/11/2023
Chairman - 01/06/2023
Director/Board Member 60 08/03/2023
Date Insider Type Main position Quantity % Market Cap.
5/3/26 A Buy 23,615 0.0087%
5/1/26 A Buy

Chairman

25,000 0.0092%
2/25/26 A Buy

Chairman

32,500 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%-2.07%-46.62%+94.52% 135M
-0.71%+6.72%+18.80%-0.46% 211B
-0.52%-6.05%-6.80%-25.11% 135B
+1.65%-2.29%-31.94%+1.99% 119B
+1.54%+0.50%-58.31%-15.57% 65.77B
-1.42%-3.62%+3.29%-9.87% 47.58B
+3.03%-0.17%-26.91%-33.60% 44.44B
-0.84%+5.41%+15.30%+8.84% 39.14B
-2.02%+1.54%+23.68%+30.76% 36.79B
-1.41%+3.99%+77.58%+2.50% 29.37B
Average -0.14%+0.22%-3.19%+5.40% 72.82B
Weighted average by Cap. -0.00%+0.37%-2.59%-6.40%

Financials

2026 *2027 *
Net sales 11.45M 8.01M 7.03M 6.54M 6M 11.28M 771M 77.66M 30.34M 379M 30.06M 29.41M 1.31B 21.55M 15.07M 13.24M 12.31M 11.3M 21.22M 1.45B 146M 57.11M 713M 56.57M 55.35M 2.47B
Net income -12.7M -8.88M -7.8M -7.25M -6.66M -12.51M -855M -86.14M -33.65M -420M -33.34M -32.62M -1.45B -8.55M -5.98M -5.25M -4.88M -4.48M -8.42M -576M -57.99M -22.66M -283M -22.45M -21.96M -979M
Net Debt -40.7M -28.46M -25M -23.25M -21.33M -40.08M -2.74B -276M -108M -1.35B -107M -105M -4.66B -29.5M -20.63M -18.12M -16.85M -15.46M -29.05M -1.99B -200M -78.17M -977M -77.44M -75.77M -3.38B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
24/07/26 A$0.7100 -0.70% 61,960
23/07/26 A$0.7150 -0.69% 186,504
22/07/26 A$0.7200 +0.70% 226,469
21/07/26 A$0.7150 -0.69% 178,452
20/07/26 A$0.7200 -0.69% 247,192
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7100AUD
Average target price
1.225AUD
Spread / Average Target
+72.54%

Quarterly revenue - Rate of surprise